SOHO State-of-the-Art Updates and Next Questions: Treatment for Newly Diagnosed Peripheral T-Cell Lymphomas
Clinical Lymphoma Myeloma and Leukemia · 2024
DOI: 10.1016/j.clml.2023.10.007 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2024. Verfasst von Jackson S Burton und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Oncology, Washington University in St. Louis School of Medicine, St. Louis, MO. Hauptthemen laut MEDLINE: Lymphoma, T-Cell, Peripheral. Die Arbeit nennt 103 Literaturangaben. Gefördert von: Leukemia and Lymphoma Society.
Abstract (Originalsprache)
Although a rare subset of non-Hodgkin lymphomas, peripheral T-cell lymphomas (PTCL) account for a disproportionate proportion of patient mortality. Conventional therapies are derived from experience treating aggressive B-cell lymphomas and center around CHOP-based chemotherapy. However, due to the unique biology and diverse subtypes of PTCL, most patients fail to durably respond to this approach and 5-year survival is only 20% to 30%. There have been multiple attempts to improve outcomes for patients with PTCL. Among the more successful strategies are the use of consolidative autologous stem cell transplant, the augmentation of CHOP with etoposide (CHOEP), and the use of brentuximab vedotin in CD30-positive PTCL. Advances in the understanding of histology-specific biology has cultivated enthusiasm to evaluate hypomethylating agents, histone deacetylate inhibitors, and phosphoinositol-3-kinase inhibitors in the frontline setting. Improvements in monitoring disease response and prognostication including the use of cell-free DNA, mutational profiling, and interim PET/CT imaging are also on the horizon. For patients with acute T-cell leukemia/lymphoma, the use of mogamulizumab-based therapy in the frontline setting may lead to advances in care. The true impact of these new-era therapies will only be elucidated as clinical practices incorporate the rapidly changing evidence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Oncology, Washington University in St. Louis School of Medicine, St. Louis, MO.
- Department of Medicine, Division of Oncology, Washington University in St. Louis School of Medicine, St. Louis, MO. Electronic address: mehta-n@wustl.edu.
Förderung
- Leukemia and Lymphoma Society
Zitieren
APA
Burton, J. S., Foley, N. C., & Mehta-Shah, N. (2024). SOHO State-of-the-Art Updates and Next Questions: Treatment for Newly Diagnosed Peripheral T-Cell Lymphomas. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2023.10.007
Vancouver
Burton JS, Foley NC, Mehta-Shah N. SOHO State-of-the-Art Updates and Next Questions: Treatment for Newly Diagnosed Peripheral T-Cell Lymphomas. Clinical Lymphoma Myeloma and Leukemia. 2024. doi:10.1016/j.clml.2023.10.007
BibTeX
@article{Burton2024,
author = {Burton, Jackson S and Foley, Nicole C and Mehta-Shah, Neha},
title = {SOHO State-of-the-Art Updates and Next Questions: Treatment for Newly Diagnosed Peripheral T-Cell Lymphomas},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2024},
doi = {10.1016/j.clml.2023.10.007}
}
EUVIMED